Company / Cash & Equivalents
10x Genomics, Inc. Cash & Equivalents History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$344.1M
FY2024
5-year range
$344.1M / $663.6M
FY2020-FY2024
Trend
-4.2%
vs FY2023
Sector context
#63 of 148
Health Care
What the data says
At $344M, 10x Genomics, Inc.'s cash & equivalents ranks #63 of 148 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $664M in FY2021 to $344M in FY2024.
Based on SEC 10-K filings.
$344M in FY2024 with a 5-year CAGR of -4.1%.
Declined from $587M to $344M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.7%
- 5-Year CAGR
- -4.1%
- 10-Year CAGR
- -
Sector benchmark
#63 of 148 in Health CareTop 43% of 148This company $344.1M Sector average $1.2B
▼
-70.8% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -4.1%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 4.2% year-over-year.
- Ranks #63 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $344.1M | -4.2% |
| FY2023 | $359.3M | -38.8% |
| FY2022 | $587.4M | -11.5% |
| FY2021 | $663.6M | +0.0% |
| FY2020 | $663.6M | +56.4% |
| FY2019 | $424.2M | +551.8% |
| FY2018 | $65.1M | +36.0% |
| FY2017 | $47.9M | - |
As of FY2024 · SEC 10-K · Updated Jul 1, 2026